EMA consults on definition of starting materials for specific biological medicines
This article was originally published in SRA
The European Medicines Agency has published a draft reflection paper to help manufacturers preparing marketing authorisation dossiers understand what would constitute a "starting material" in the case of specific groups of biological medicines1. The paper, which clarifies the definition of starting materials for such products, also addresses the extent to which any variability in the early manufacturing steps for the biologics would be acceptable.
You may also be interested in...
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.
Differences between how Australia and the EU define “central circulatory system” has resulted in different risk classification levels being assigned to some devices in the two jurisdictions.